# Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC

> **NCT06348797** · PHASE1 · RECRUITING · sponsor: **Sichuan University** · enrollment: 28 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** α-PD-L1/4-1BB DLL3 CAR-T (BHP01)

## Key facts

- **NCT ID:** NCT06348797
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-03
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06348797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06348797, "Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT06348797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*